Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19841041 | 0.88 | GABRP (0.36) | PRKCIMEN1CYP3A4KMT2A | |
| SCHEMBL18258090 | 0.84 | ALDH1A1 (0.30) | — | |
| SCHEMBL15782877 | 0.73 | KDM4E (0.38) | PRKCI | |
| SCHEMBL15782884 | 0.71 | PRKCI (0.35) | PRKCIHSD17B1MEN1CYP3A4HPGD | |
| SCHEMBL15782871 | 0.71 | PRKCI (0.33) | PRKCIHSD17B1MEN1CYP3A4HPGD | |
| SCHEMBL15782879 | 0.69 | SLC2A1 (0.36) | PRKCIMEN1CYP3A4HPGDKMT2A | |
| SCHEMBL12948357 | 0.69 | MTNR1A (0.36) | PRKCIMEN1CYP3A4HPGDKMT2A | |
| SCHEMBL15782880 | 0.69 | PRKCI (0.33) | PRKCIBAZ2AMEN1CYP3A4HPGD | |
| SCHEMBL21913395 | 0.68 | EGFR (0.31) | — | |
| SCHEMBL25065174 | 0.67 | EGFR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138831-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | President and Fellows of Harvard College (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-1753713-B1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | HARVARD COLLEGE (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9365493-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | PRKCI 2091/4885HSD17B1 1662/4885BAZ2A 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.